MENU
+Compare
CLLS
Stock ticker: NASDAQ
AS OF
Apr 9, 03:31 PM (EDT)
Price
$1.25
Change
+$0.03 (+2.46%)
Capitalization
157M

CLLS Cellectis SA Forecast, Technical & Fundamental Analysis

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications... Show more

Industry: #Biotechnology
CLLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for CLLS with price predictions
Apr 08, 2025

CLLS in upward trend: price expected to rise as it breaks its lower Bollinger Band on April 03, 2025

CLLS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 33 cases where CLLS's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CLLS's RSI Indicator exited the oversold zone, of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 65 cases where CLLS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CLLS advanced for three days, in of 238 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on April 02, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on CLLS as a result. In of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for CLLS turned negative on April 04, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLLS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for CLLS entered a downward trend on March 25, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.930) is normal, around the industry mean (12.883). P/E Ratio (0.000) is within average values for comparable stocks, (61.746). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.735). Dividend Yield (0.000) settles around the average of (0.026) among similar stocks. P/S Ratio (2.657) is also within normal values, averaging (239.728).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. CLLS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLLS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
CLLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

CLLS is expected to report earnings to rise 50.06% to -24 cents per share on May 07

Cellectis SA CLLS Stock Earnings Reports
Q1'25
Est.
$-0.24
Q4'24
Missed
by $0.07
Q3'24
Missed
by $0.03
Q2'24
Beat
by $0.01
Q1'24
Beat
by $0.41
The last earnings report on March 14 showed earnings per share of -15 cents, missing the estimate of -9 cents. With 29.84K shares outstanding, the current market capitalization sits at 157.00M.
A.I. Advisor
published General Information

General Information

a genome engineering company of pre-engineered products for pharmaceutical industry, cell therapies, seed companies, and laboratory researchers

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
8, rue de la Croix Jarry
Phone
+33 181691600
Employees
285
Web
https://www.cellectis.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SPY496.48-7.90
-1.57%
SPDR® S&P 500® ETF
GME23.39-0.90
-3.71%
GameStop Corp
BTC.X76271.950000-2963.382800
-3.74%
Bitcoin cryptocurrency
TSLA221.86-11.43
-4.90%
Tesla
AAPL172.42-9.04
-4.98%
Apple

CLLS and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, CLLS has been loosely correlated with SLN. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if CLLS jumps, then SLN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLLS
1D Price
Change %
CLLS100%
+5.00%
SLN - CLLS
43%
Loosely correlated
-3.36%
PMVP - CLLS
39%
Loosely correlated
-6.25%
TGTX - CLLS
36%
Loosely correlated
-4.62%
CLGN - CLLS
33%
Poorly correlated
+0.46%
DTIL - CLLS
32%
Poorly correlated
+5.00%
More